Alitalo KK - Search Results

1

Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib.

Crona DJ, Skol AD, Leppänen VM, Glubb DM, Etheridge AS, Hilliard E, Peña CE, Peterson YK, Klauber-DeMore N, Alitalo KK, Innocenti F. Crona DJ, et al. Among authors: alitalo kk. Cancer Res. 2019 Jan 1;79(1):231-241. doi: 10.1158/0008-5472.CAN-18-1089. Epub 2018 Nov 1. Cancer Res. 2019. PMID: 30385613 Free PMC article. Clinical Trial.

2

FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter.

Aprelikova O, Pajusola K, Partanen J, Armstrong E, Alitalo R, Bailey SK, McMahon J, Wasmuth J, Huebner K, Alitalo K. Aprelikova O, et al. Cancer Res. 1992 Feb 1;52(3):746-8. Cancer Res. 1992. PMID: 1310071

3

FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines.

Pajusola K, Aprelikova O, Korhonen J, Kaipainen A, Pertovaara L, Alitalo R, Alitalo K. Pajusola K, et al. Cancer Res. 1992 Oct 15;52(20):5738-43. Cancer Res. 1992. PMID: 1327515

4

Enhanced expression of the tie receptor tyrosine kinase mesenger RNA in the vascular endothelium of metastatic melanomas.

Kaipainen A, Vlaykova T, Hatva E, Böhling T, Jekunen A, Pyrhönen S, Alitalo K. Kaipainen A, et al. Cancer Res. 1994 Dec 15;54(24):6571-7. Cancer Res. 1994. PMID: 7987857

5

Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3.

Jussila L, Valtola R, Partanen TA, Salven P, Heikkilä P, Matikainen MT, Renkonen R, Kaipainen A, Detmar M, Tschachler E, Alitalo R, Alitalo K. Jussila L, et al. Cancer Res. 1998 Apr 15;58(8):1599-604. Cancer Res. 1998. PMID: 9563467

6

Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors.

Partanen TA, Alitalo K, Miettinen M. Partanen TA, et al. Cancer. 1999 Dec 1;86(11):2406-12. Cancer. 1999. PMID: 10590384

7

Regulation of angiogenesis via vascular endothelial growth factor receptors.

Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Veikkola T, et al. Cancer Res. 2000 Jan 15;60(2):203-12. Cancer Res. 2000. PMID: 10667560 Review. No abstract available.

8

Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.

Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Ylä-Herttuala S, Jäättelä M, Alitalo K. Karpanen T, et al. Cancer Res. 2001 Mar 1;61(5):1786-90. Cancer Res. 2001. PMID: 11280723

9

Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.

He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. He Y, et al. Cancer Res. 2005 Jun 1;65(11):4739-46. doi: 10.1158/0008-5472.CAN-04-4576. Cancer Res. 2005. PMID: 15930292

10

Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.

Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L, Alitalo K. Laakkonen P, et al. Cancer Res. 2007 Jan 15;67(2):593-9. doi: 10.1158/0008-5472.CAN-06-3567. Cancer Res. 2007. PMID: 17234768

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

705 results

Search Page